Clinical Trials
27 trialsNCT02617277 2026-03-04
Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT02513563 2026-02-19
AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01849146 2025-01-09
Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT03028766 2024-09-19
WISTERIA
University of Birmingham
Phase 1 Completed
NCT02937818 2024-06-07
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
AstraZeneca
Phase 2 Completed
NCT01922076 2024-01-31
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT03253679 2023-10-17
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification
National Cancer Institute (NCI)
Phase 2 Completed
NCT02272790 2023-10-03
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
AstraZeneca
Phase 2 Completed
NCT01827384 2023-09-29
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
National Cancer Institute (NCI)
Phase 2 Completed
NCT02095132 2023-09-26
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00648648 2023-09-21
MK-1775-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01357161 2023-09-21
A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01164995 2023-09-07
M10MKO
The Netherlands Cancer Institute
Phase 2 Completed
NCT02482311 2023-07-03
Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT02610075 2023-07-03
Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.
AstraZeneca
Phase 1 Completed
NCT02194829 2023-04-25
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT04462952 2022-07-25
Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT03012477 2021-11-23
CISPLATIN + AZD-1775 In Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01748825 2021-07-26
AZD1775 for Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02585973 2021-06-29
Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT02593019 2021-03-19
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients
Samsung Medical Center
Phase 2 Completed
NCT02207010 2020-12-10
A Phase 0 Study of AZD1775 in Recurrent GBM Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Completed
NCT02906059 2020-10-12
Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer
NYU Langone Health
Phase 1 Completed
NCT02511795 2019-11-07
AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors
AstraZeneca
Phase 1 Completed
NCT02666950 2019-09-06
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Mayo Clinic
Phase 2 Completed
NCT02341456 2019-03-25
Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours
AstraZeneca
Phase 1 Completed
NCT02508246 2019-03-13
WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck
University of Washington
Phase 1 Completed